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Abstract 
Background: Previous studies of the association between intake of dairy products and 
colorectal cancer risk have indicated an inverse association with milk, however, the evidence 
for cheese or other dairy products is inconsistent. 
Methods: We conducted a systematic review and meta-analysis to clarify the shape of the 
dose–response relationship between dairy products and colorectal cancer risk. We searched 
the PubMed database for prospective studies published up to May 2010. Summary relative 
risks (RRs) were estimated using a random effects model. 
Results: Nineteen cohort studies were included. The summary RR was 0.83 (95% CI 
[confidence interval]: 0.78–0.88, I2 = 25%) per 400 g/day of total dairy products, 0.91 (95% 
CI: 0.85–0.94, I2 = 0%) per 200 g/day of milk intake and 0.96 (95% CI: 0.83–1.12, I2 = 28%) 
per 50 g/day of cheese. Inverse associations were observed in both men and women but were 
restricted to colon cancer. There was evidence of a nonlinear association between milk and 
total dairy products and colorectal cancer risk, P < 0.001, and the inverse associations 
appeared to be the strongest at the higher range of intake. 
Conclusion: This meta-analysis shows that milk and total dairy products, but not cheese or 
other dairy products, are associated with a reduction in colorectal cancer risk. 
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Introduction 
 
Colorectal cancer is the third most common type of cancer worldwide with ~1.2 million new 
cases diagnosed in 2008accounting for 9.7% of all incident cancers [1]. Ecological, secular 
trend and migration studies have provided strong evidence that environmental factors 
including lifestyle are likely to be the main determinants of colorectal cancer risk [2–
4].Dietary factors are known to be important risk factors for colorectal cancer, but to date, 
only intakes of alcohol (among men) and red and processed meat are considered to be 
convincing dietary causes of colorectal cancer [5]. 
 
Dairy products have been hypothesized to protect against colorectal cancer risk due to their 
high calcium content, which may bind pro-inflammatory secondary bile acids and ionized 
fatty acids and may reduce cell proliferation and promote cell differentiation[6, 7]. However, 
some dairy products, such as certain cheeses and creams, also have a high-fat content that 
potentially could increase colorectal cancer risk by increasing bile acid levels in the colon 
[8].Epidemiological studies of dairy products and colorectal cancer risk have provided mixed 
results [9–24]. Some cohort studies have reported inverse associations between intake of total 
dairy products, milk and/or yogurt and colorectal cancer risk [14, 16, 23, 24],however, other 
studies found no association [9–13, 15, 17–22]. In the second report from the World Cancer 
Research Fund/American Institute for Cancer Research (WCR/AICR) published in 
2007‘Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective’, 
it was stated that milk intake probably protects against colorectal cancer, but there was 
limited suggestive evidence that intake of cheese increases risk [5]. Because there also was 
evidence that high calcium and dairy intake increases prostate cancer risk, no 
recommendation was provided with regard to intakes of dairy products. For future 
recommendations to be made with regard to dairy product intake, it will be important to 
clarify the shape of the dose–response relationship and whether there are any gender-specific 
differences in the risk. In addition, further exploration of possible confounding by other 
lifestyle factors is needed to firmly establish the potential preventive role of dairy products in 
colorectal cancer etiology. A number of additional studies have been published since the 
second WCRF/AICR report[25–30] and here we update the evidence up to May 2010 with a 
specific aim to address whether the association differs by gender and if there is a nonlinear 
association between intake of dairy products and colorectal cancer risk. 
 
Methods 
Search strategy 
We updated the systematic literature review published in 2007 [5] by searching the PubMed 
database up to May 2010 for cohort studies of dairy product intake and colorectal cancer risk. 
We followed a predefined protocol for the review 
(http://www.dietandcancerreport.org/downloads/SLR_Manual.pdf), which includes details of 
the search terms used. We also searched the reference lists of all the studies that were 
included in our analysis as well as those listed in the published systematic reviews and 
meta-analyses [31, 32]. We followed standard criteria for conducting and reporting meta-
analyses [33]. 
 
Study selection 
We included prospective cohort, case–cohort and nested case–control studies of total dairy 
products or specific types of dairy products and colorectal cancer incidence. To be included 
in the analyses, estimates of the relative risk (RR) (such as hazard ratio or risk ratio) with the 
95% confidence intervals (CIs) had to be available in the publication. For the dose–response 
analysis, a quantitative measure of intake had to be provided. When there were several 
publications from the same study, we selected the publication with the largest number of 
cases. If all the required information was not provided in the paper, we used the publication 
that presented the results with sufficient information to be incorporated into the dose–
response analyses. Thirty-five potentially relevant full-text publications [9–30, 34–46] were 
identified. We excluded seven publications of colorectal cancer mortality [36, 37, 40, 42–45], 
one publication reporting on childhood dairy intake that only had information on intake by 
household level [46], two publications that did not provide risk estimates [38] or CIs [39] and 
one duplicate publication [41]. For the dose–response analysis, we further excluded one 
publication because no quantities of the intake were provided [14], and four others because 
only the highest versus the lowest level of intake was reported [11, 28, 34, 35]. 
 
Data extraction 
The following data were extracted from each study: The first author’s last name, publication 
year, country where the study was conducted, the study name, follow-up period, sample size, 
gender, age, number of cases, dietary assessment method (type, number of food items and 
whether it had been validated), type of dairy product (total dairy, milk, cheese etc.), quantity 
of intake, RRs and 95% CIs for dairy product intake and variables adjusted for in the 
analysis. The search and data extraction of articles published up to June 2006 was conducted 
by several reviewers at Wageningen University during the systematic literature review for the 
WCRF/AICR report 
(http://www.dietandcancerreport.org/downloads/SLR/Colon_and_Rectum_SLR.pdf). The 
search from June 2006 to May 2010 was conducted by two of the authors (DSMC and RL). 
Data was extracted into a database by three authors (DSMC, RL and DA). 
 
Statistical methods 
Random effects models were used to calculate summary RRs and 95% CIs for the highest 
versus the lowest level of dairy product intake and for the dose–response analysis [47]. The 
natural logarithm of the RR from each study was weighted by the inverse of its variance and 
pooled across studies. A two-tailed P < 0.05 was considered statistically significant. When 
results were reported separately for men and women, but not combined, we combined the two 
results first using a fixed-effects model to obtain an overall estimate for both the sexes 
combined, before pooling with other studies. 
 
For the dose–response analysis, we used the method described by Greenland and Longnecker 
[48] to compute study-specific slopes (linear trends) and 95% CIs from the natural logs of the 
RRs and CIs across categories of dairy product intake. The method requires that the 
distribution of cases and person-years or noncases and the RRs with the variance estimates 
for at least three quantitative exposure categories are known. We estimated the distribution of 
cases and person-years in studies that did not report these, but reported the total number of 
cases/person-years, if dairy intake was analyzed by quantiles (and could be approximated), 
e.g., the total number of person-years was divided by 5 when data were analyzed by quintiles 
in order to derive the number of person-years in each quintile. If this information was missing 
and the results were reported by functional categories (e.g. <1, 1–3, 4–6, and ≥7 servings per 
week), we used variance-weighted least squares regression to estimate the slopes. The median 
or mean level of dairy product intake in each category of intake was assigned to the 
corresponding RR for each study. For studies that reported dairy product intake by ranges of 
intake, we estimated the midpoint in each category by calculating the average of the lower 
and upper bound. When the highest or the lowest category was openended, it was assumed 
that the open-ended interval length had the same length as the adjacent interval. If the intakes 
were reported in densities (i.e. g per 1000 kcal), we recalculated the reported intakes to 
absolute intakes using the mean or median energy intake reported in the publication [27, 
29]. When studies reported the intake in servings and times per day or week, we converted 
the intakes to grams of intake per day using standard units of 244 g (or 244 ml) for milk, 43 g 
for cheese (two slices) and 177 g for total dairy products based on serving sizes reported in 
the ‘United States Department of Agriculture Food and Nutrient Database for Dietary 
Studies’ [49]. For one study that reported cheese intake in slices per week and per day, we 
used 21.5 g as a unit for each slice [26]. The dose–response results in the forest plots are 
presented for a 400, 200 and 50 g/day increment for total dairy, total milk and cheese, 
respectively. We examined a potential nonlinear dose–response relationship between total 
dairy and total milk intakes and colorectal cancer by using fractional polynomial models [50]. 
We determined the best-fitting second order fractional polynomial regression model, defined 
as the one with the lowest deviance. A likelihood ratio test was used to assess the difference 
between the nonlinear and linear models to test for nonlinearity [51]. 
 
Heterogeneity between the studies was assessed by I
2
, which is the amount of total variation 
that is explained by the between-study variation and the Q test [52]. Subgroup and meta-
regression analyses by study characteristics were conducted to investigate potential sources 
of heterogeneity. Publication bias was assessed with funnel plots, Egger’s test [53] and with 
Begg’s test [54] with the results considered to indicate potential publication bias when P < 
0.10. We conducted sensitivity analyses excluding one study at a time to explore whether the 
results were robust. Stata version 10.1 software (StataCorp, College Station, TX) was used 
for the statistical analyses. 
 
Results 
 
Nineteen cohort studies (24 publications) [9–30, 34, 35] could be included in the analysis of 
the highest versus the lowest dairy product intake and colorectal cancer risk and 17 of these 
studies (18 publications) [9, 10, 12, 13, 15–20, 22–27, 29, 30] were included in the dose–
response analysis (Supplemental Table S1, available at Annals of Oncology online; Figure 1). 
Eight of the studies were from Europe, nine from the United States and two from Asia. All 
studies provided adjusted risk estimates. A summary of the study characteristics of the 
included studies is provided in the Supplemental Table S1 (available at Annals of 
Oncology online). 
 
  
Total dairy products 
 
High versus low analysis.  
Twelve cohort studies [14, 16–19, 22, 23, 25–29] investigated the association between high 
versus low total dairy product intake and colorectal cancer risk and included 11 579 cases 
among 1 170 942 participants. The summary RR for all studies was 0.81 (95% CI: 0.74–
0.90), with moderate heterogeneity, I
2
 = 42% and Pheterogeneity = 0.06 (Figure 2A). The 
association was in the direction of decreased risk for colon cancer [9, 17–19, 26], summary 
RR = 0.72 (95% CI: 0.51–1.02, I2 = 50%, Pheterogeneity = 0.09, n = 5), but not statistically 
significant, while no association was observed for rectal cancer [17–19, 26, 34], summary RR 
= 0.96 (95% CI: 0.65–1.41, I2 = 44%, Pheterogeneity = 0.13, n = 5) (results not shown). 
 
Dose–response analysis.  
Ten cohort studies [16–19, 22, 23, 25–27, 29] were included in the dose–response analysis of 
total dairy product intake and colorectal cancer risk. The summary RR per 400 g increase per 
day (g/day) was 0.83 (95% CI: 0.78–0.88) with little evidence of heterogeneity, I2 = 25% and 
Pheterogeneity = 0.22 (Figure 2B). There was a significant inverse association for colon cancer 
(RR = 0.84, 95% CI: 0.72–0.97) but not for rectal cancer (Table 1). The summary RR for 
colorectal cancer ranged from 0.80 (95% CI: 0.77–0.84) when the Swedish Mammography 
Cohort study was excluded to 0.85 (95% CI: 0.81–0.89) when the Cohort of Swedish Men 
was excluded. There was no indication of publication bias with Egger’s test 
(P = 0.58) or with Begg’s test (P = 0.79). There was statistical evidence of a nonlinear 
association between total dairy product intake and colorectal cancer risk, P for nonlinearity < 
0.001, though the nonlinearity was observed at intakes below ~100 g/day, for which there 
was no evidence of decreased colorectal cancer risk. The association appeared broadly linear 
above this range of intake (Figure 3A). 
 
Milk 
 
High versus low analysis.  
Ten cohort studies [10, 11, 17, 19, 20, 22, 23, 26, 27, 30] were included in the analysis of 
high versus low milk intake and colorectal cancer risk, including a total of 5011 cases among 
655 483 participants. The summary RR was 0.83 (95% CI: 0.74–0.93) for colorectal cancer, 
with low heterogeneity, I
2
 = 14% and Pheterogeneity = 0.31 (Figure 4A). The summary RR was 
0.82 (95% CI: 0.72–0.94, I2 = 0%, Pheterogeneity = 0.54, n = 7) for colon cancer [13, 17, 19, 26, 
30, 35] and 0.79 (95% CI: 0.60–1.06, I2 = 0%, Pheterogeneity = 0.79, n = 4) for rectal cancer [17, 
19, 26, 30] (results not shown). 
 
Dose–response analysis.  
Nine cohort studies [10, 17, 19, 20, 22, 23, 26, 27, 30] were included in the dose–response 
analysis for colorectal cancer. The summary RR for a 200 g/day increase in the intake was 
0.90 (95% CI: 0.85–0.94), with no evidence of heterogeneity, I2 = 0% and Pheterogeneity = 0.62 
(Figure 4B). The inverse association was statistically significant only for colon cancer 
(summary RR = 0.88, 95% CI: 0.79–0.97, I2 = 44%, Pheterogeneity = 0.11) (Table 1). In a 
sensitivity analysis, the summary RR for colorectal cancer ranged from 0.87 (95% CI: 
0.83–0.92) when excluding the Cancer Prevention Study II Nutrition Cohort to 0.91 (95% CI: 
0.86–0.96) when excluding the Cohort of Swedish men. There was no indication of 
publication bias with Egger’s test (P = 0.86) or with Begg’s test (P = 0.84). There was 
evidence of a nonlinear association between milk intake and colorectal cancer risk, P for 
nonlinearity < 0.001, with no substantial association below ~200 g/day and with the greatest 
reduction over the higher levels of intake (a 20%–30% reduction in risk at levels between 
500 and 800 g/day) (Figure 3B). 
 
Cheese 
 
High versus low analysis.  
Seven cohort studies [10, 17, 20, 22–24, 26] were included in the analysis of cheese intake 
and colorectal cancer risk and included 1635 cases among 177 551 participants. The 
summary RR was 0.94 (95% CI: 0.75–1.18) and there was moderate heterogeneity, I2 = 39% 
and Pheterogeneity = 0.14 (Figure 5A). The summary RR was 1.04 (95% CI: 0.69–1.55, I
2
 = 
58%, Pheterogeneity = 0.05, n = 5) for colon cancer [12, 15, 17, 24, 26] and 0.88 (95% CI: 0.59–
1.30, I
2 
= 0%, Pheterogeneity = 0.84, n = 3) for rectal cancer [17, 24, 26] (results not shown). 
 
  
Dose–response analysis. 
Seven cohort studies [10, 17, 20, 22–24, 26] were included in the dose–response analysis for 
colorectal cancer. The summary RR per 50 g/day was 0.96 (95% CI: 0.83–1.12), with no 
indication of heterogeneity, I
2
 = 28% and Pheterogeneity = 0.22 (Figure 5B). There was no 
significant association between cheese intake and either colon or rectal cancer (Table 1). 
 
Other dairy products 
Other specific types of dairy products including high-fat dairy products [9, 21, 24], low-fat 
dairy products [18, 21], cottage cheese [15, 17, 23, 26], fermented dairy products [10, 12, 16, 
18, 22], fermented milk [17, 24, 26, 35], yogurt [22, 23] and butter [17, 24] were not 
significantly associated with risk (Table 2). Studies of ice-cream [12], nonfermented dairy 
products [18], low-fat milk [15] and non-fat milk [15] also found no significant association. 
 
 
Subgroup, sensitivity and meta-regression analyses.  
 
In subgroup analyses of total dairy and milk intake and colorectal cancer, there were inverse 
associations in most, but not all strata of the study characteristics (Table 1). In the meta-
regression analyses, none of the variables investigated significantly explained the 
heterogeneity observed in the data (which anyway was low or moderate in most of the 
analyses), although for cheese, there was borderline significant heterogeneity between studies 
that adjusted and did not adjust for red meat intake (Pheterogeneity = 0.07), with a significant 
inverse association among studies that adjusted for red meat but a nonsignificant positive 
association among studies that did not adjust for red meat. 
 
In a sensitivity analysis, we explored whether exclusion of studies from the dose–response 
meta-analyses affected our results. When we repeated the high versus low intake analyses 
with the same studies as in the dose–response analysis, the summary RR for total dairy 
products was 0.79 (95% CI: 0.71–0.88, I2 = 37%, Pheterogeneity = 0.11) and for milk was 0.83 
(95% CI: 0.73–0.94, I2 = 23%, Pheterogeneity = 0.24). We further repeated the high versus low 
analyses including studies that reported on total dairy products [40], total milk [36, 42, 43] 
and cheese [36, 42, 43] in relation to colorectal cancer mortality. However, the results were 
similar, summary RR = 0.81 (95% CI: 0.73–0.89, I2 = 40%, Pheterogeneity = 0.07) for total dairy 
products, summary RR = 0.84 (95% CI: 0.75–0.95, I2 = 24%, Pheterogeneity = 0.20) for total 
milk and summary RR = 1.02 (95% CI: 0.84–1.23, I2 = 34%, Pheterogeneity = 0.15) for cheese. 
 
 
Discussion 
In this meta-analysis, high intakes of milk and total dairy products were associated with a 
statistically significant reduction in colorectal cancer risk as compared with low intake. There 
were significant inverse associations both among men and women for colorectal cancer, but 
when stratified by cancer site the inverse associations were only present for colon cancer. 
There was evidence of a nonlinear association for both total dairy and milk, with the strongest 
reduction in risk at the higher level of intake, but for total dairy the nonlinearity may have 
been an artifact related to a small group of nonconsumers. Intake of cheese or other specific 
dairy products was not significantly associated with colorectal cancer risk, although the 
number of studies was small.  
 
The results from this meta-analysis are consistent with two previous meta-analyses of case–
control and cohort studies [31, 32] and a pooled analysis of ten cohort studies [55], which 
found inverse associations between intake of dairy products and milk and colorectal cancer 
risk. However, in contrast to the two previous meta-analyses on the subject that only 
conducted analyses of the highest versus the lowest intake [31, 32], we further quantified the 
association between milk and dairy product intakes and colorectal cancer risk by conducting 
linear and nonlinear dose–response analyses, and in addition, we also conducted detailed 
subgroup analyses to identify potential sources of heterogeneity. In the most recent report 
from the WCRF/AICR, it was stated that milk intake probably protects against colorectal 
cancer risk, while there was limited suggestive evidence that cheese increases risk. No 
judgment was provided for total dairy product intake, but our results suggest a protective 
effect. However, the result for total dairy product intake may largely be driven by an effect of 
milk intake, as milk accounts for a large part of total dairy intakes in most populations. The 
difference between our results and the results from the report, with regard to cheese intake, 
may partly be due to two additional studies having been published after the report was 
completed [24, 26], which found inverse associations, thus driving the overall result toward 
the null. These additional studies may also have adjusted for more dietary confounders than 
several older studies. The inverse associations with milk and total dairy products were 
restricted to colon cancer, in contrast to the results from the pooled analysis where an inverse 
association with milk intake was also observed for rectal cancer [55]. However, fewer studies 
were included in our rectal cancer analysis compared with the pooled analysis, thus we may 
have had limited statistical power in this subgroup analysis.  
 
Our meta-analysis may have several limitations that need to be addressed. Because of the 
observational nature of the data, it is possible that the observed inverse association between 
milk and total dairy product intakes and colorectal cancer risk could be due to unmeasured or 
residual confounding. Higher intake of milk and dairy products may be associated with other 
health behaviors including higher levels of physical activity, lower prevalence of smoking 
and overweight/obesity and lower intakes of alcohol and red and processed meat [27, 29], 
although it is also possible that different types of dairy products may be differentially 
associated with some of these confounders [24]. However, many of the studies adjusted for 
known confounding factors such as age, body mass index, smoking, alcohol, red and 
processed meat and energy intake. In addition, the results were generally similar in the 
subgroup analyses when we stratified the results according to adjustment for confounding 
factors or other study characteristics, with no heterogeneity between subgroups for total dairy 
products and milk. Only in the analysis of cheese was there some indication of heterogeneity 
between studies with and without adjustment for red meat with an inverse association in 
studies that adjusted for red meat, while studies without adjustment for red meat showed a 
nonsignificant positive association, suggesting potential confounding. Nevertheless, because 
of the few studies in these subgroups any future studies could clarify this finding.  
 
Although publication bias can be a problem in meta-analyses of published literature, we 
found no evidence of such bias in this analysis. The few studies that were excluded from the 
dose– response analysis are not likely to have altered the results, because when we repeated 
the high versus low analyses with the same dataset as in the dose–response analyses, the 
results were very similar. Because of the few studies that reported on other specific types of 
dairy products (except milk and cheese), we may have had limited statistical power to detect 
associations with these items. Measurement errors in the assessment of dietary intake are 
known to bias effect the estimates. However, biases are most likely to be toward the null. 
Dietary changes after baseline may also attenuate associations between dietary intake and 
cancer risk, however, the only study that had updated dietary information available for the 
analyses found similar results when using cumulative updated and baseline questionnaires for 
the analyses [11]. Almost all the studies included in our meta-analysis used validated food-
frequency questionnaires, but none of the studies made any corrections for measurement error 
in their analyses. Nevertheless, several validation studies have shown that dairy product 
intake can be assessed relatively well with food-frequency questionnaires and reported 
correlation coefficients of 0.6–0.8 between intake of dairy foods assessed by food diaries or 
food records and food-frequency questionnaires [56–58].  
 
Several mechanisms may explain a protective effect of dairy foods upon colorectal cancer 
risk [24, 31]. Dairy products are one of the main dietary sources of calcium, which has been 
hypothesized to prevent colon cancer by binding secondary bile acids and ionized fatty acids 
and thus reduce their proliferative effects in the colonic epithelium [6]. In addition, it has 
been shown that calcium can influence multiple intracellular pathways leading to 
differentiation in normal cells and apoptosis in transformed cells [7] and that calcium can 
reduce the number of mutations in the K-ras gene in rat colorectal neoplasms [59]. Several 
clinical trials have reported reduced cell proliferation in the colon and rectum with intake of 
calcium and dairy products [60–64] and other trials have found reduced risk of colorectal 
adenoma recurrence with calcium sup-plementation [65]. In the most recent report from the 
WCRF/AICR, it was stated that high calcium intake probably protects against colorectal 
cancer [5]. Some fat components of dairy products including conjugated linoleic acid and 
butyric acid have been shown to be protective in experimental studies [66, 67], but few 
studies were available for our analysis of high-fat dairy products [9, 21, 24]. Other possible 
protective components of dairy products include lactoferrin [68], lactic acid bacteria in 
fermented dairy products [31] and vitamin D in fortified dairy products [31, 69].  
 
Our meta-analysis has several strengths. Because we based our analyses on prospective 
studies, we have effectively avoided recall and selection bias. There was little evidence of 
heterogeneity in the analyses except for the high versus the low analysis of total dairy 
products. This was probably due to differences in intake levels across studies because when 
the level of intake was taken into account in the dose–response analysis there was no 
significant heterogeneity, confirming the importance of conducting dose–response analyses. 
The studies included a large number of cases and participants, with a total of ~650 000 and 
1.2 million participants and 5000 and 11 500 cases in the analyses of milk and total dairy 
products, respectively. Thus, we had statistical power to detect moderate and weak 
associations in the colorectal cancer analysis, although fewer studies and cases were included 
in the stratified analyses of colon and rectal cancer. Our results are comparable with the 
results of a pooled analysis of 10 cohort studies, which found a 15% reduction in colorectal 
cancer risk for high versus low intake of milk [55]. However, to our knowledge this is the 
first meta-analysis to explore a potential nonlinear association between dairy products and 
colorectal cancer risk.  
 
The interpretation of our results with regard to public health recommendations is, however, 
complicated by the fact that consumption of milk and dairy products may have both 
beneficial and adverse effects with regard to other diseases.  There is evidence of a reduced 
risk of cardiovascular disease and type 2 diabetes [70], no association with total mortality 
[71], but of an increased risk of prostate cancer [5] and Parkinson’s disease [72] with higher 
dairy intake. Thus, the question of possible threshold effects both with regard to adverse and 
beneficial effects of dairy products remains. In this analysis, the reduced risk was most 
pronounced at the higher levels of intake (e.g. equivalent to 2–3 glasses of milk per day), 
which complicates the interpretation of the findings, at least among men because of the 
increased prostate cancer risk at such levels of intake [5, 73]. Further studies of dairy intake 
in relation to other cancers and overall cancer risk and mortality are needed to better assess 
the risk–benefit of dairy product consumption, both overall and for specific types of dairy 
products, and whether any gender-specific recommendations are warranted.   
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Figure 1. Flow-chart of study selection. CI, confidence interval; WCRF, World Cancer 
Research Fund. 
 
 
 
  
Figure 2. Total dairy products and colorectal cancer. CI, confidence interval. 
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Figure 3. Total dairy products and total milk and colorectal cancer, nonlinear dose–response. 
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Figure 4. Milk and colorectal cancer. CI, confidence interval. 
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Figure 5. Cheese and colorectal cancer. CI, confidence interval. 
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Table 1. Subgroup analyses of milk and dairy product intakes and colorectal cancer, dose–response analysis 
 Dairy products Milk  Cheese  
 n RR (95% CI) I
2
 (%) Ph
1 
Ph
2
 n RR (95% CI)  I
2
 (%) Ph
1 
Ph
2
 n RR (95% CI)  I
2
 (%) Ph
1 
Ph
2
 
All studies 10 0.83 (0.78-0.88) 24.6 0.22  9 0.90 (0.85-0.94) 0 0.62  7 0.96 (0.83-1.12) 27.8 0.22  
Duration of follow-up                
    <10 yrs follow-up 4 0.90 (0.80-0.98) 8.1 0.35 0.10 6 0.88 (0.84-0.94) 0 0.50 0.30 3 0.96 (0.79-1.16) 33.2 0.22 0.95 
    ≥10 yrs follow-up 6 0.80 (0.76-0.85) 0 0.53 3 0.96 (0.84-1.11) 0 0.73 4 1.01 (0.75-1.37) 43.5 0.15 
Sex                 
    Men  5 0.81 (0.75-0.88) 30.2 0.22 0.56 3 0.86 (0.81-0.93) 0 0.40 0.32 3 0.93 (0.75-1.14) 31.2 0.23 0.68 
    Women 7 0.84 (0.76-0.93) 35.3 0.16 5 0.81 (0.59-1.11) 0 0.40 1 0.85 (0.71-1.02)   
    Men 
3
  3 0.86 (0.79-0.94) 0 0.70 0.22 2 0.89 (0.82-0.98) 0 0.70 0.47 0     
    Women 
4 
3 0.79 (0.67-0.92) 28.9 0.25 2 0.97 (0.83-1.12) 42.2 0.19 0    
Subsite                 
    Colon  5 0.84 (0.72-0.97) 35.4 0.19 0.30 6 0.88 (0.79-0.97) 44.1 0.11 0.72 5 0.84 (0.68-1.04) 8.5 0.36 0.64 
    Rectum  4 1.00 (0.77-1.28) 68.9 0.02 4 0.90 (0.79-1.02) 0 0.53 3 0.90 (0.70-1.15) 0 0.93 
    Colon 
5 
4 0.83 (0.69-0.99) 51.5 0.10 0.32 4 0.81 (0.74-0.90) 0 0.99 0.30 3 0.81 (0.64-1.02) 13.4 0.32 0.54 
    Rectum 
6 
4 1.00 (0.77-1.28) 68.9 0.02 4 0.90 (0.79-1.02) 0 0.53 3 0.90 (0.70-1.15) 0 0.93 
Geographic location                 
    Europe 5 0.84 (0.72-0.97) 63.7 0.03 1.00 5 0.86 (0.79-0.93) 0 0.58 0.34 6 0.96 (0.82-1.12) 35.8 0.17 0.60 
    America 5 0.83 (0.78-0.88) 0 0.93 3 0.92 (0.87-0.99) 0 0.62 1 1.16 (0.63-2.13)   
    Asia 0    1 0.81 (0.59-1.11)   0    
Number of cases                
    Cases <500 5 0.77 (0.70-0.83) 0 0.67 0.56 7 0.87 (0.80-0.94) 0 0.55 0.49 6 1.01 (0.86-1.18) 19.4 0.29 0.24 
    Cases 500-<1500 3 0.90 (0.81-0.99) 25.3 0.26 1 0.94 (0.83-1.05)   1 0.79 (0.62-1.02)   
    Cases ≥1500 2 0.83 (0.77-0.89) 0.0 0.58 1 0.91 (0.83-0.99)   0    
Adjustment for confounders 
Alcohol  Yes  6 0.83 (0.75-0.91) 50.6 0.07 0.79 4 0.87 (0.77-1.00) 26.2 0.25 0.27 4 0.96 (0.83-1.11) 11.9 0.33 0.83 
No  4 0.84 (0.77-0.91) 0 0.63 5 0.91 (0.86-0.97) 0 0.95 3 1.04 (0.66-1.64) 57.6 0.09 
Smoking  
 
Yes  7 0.81 (0.76-0.85) 0 0.49 0.15 6 0.89 (0.84-0.94) 0 0.47 0.60 5 0.99 (0.83-1.18) 24.3 0.26 0.58 
No  3 0.89 (0.79-1.00) 30.5 0.24 3 0.93 (0.80-1.08) 0 0.50 2 0.93 (0.62-1.41) 60.2 0.11 
Body mass index, 
weight, WHR 
Yes  9 0.83 (0.78-0.89) 32.9 0.16 0.99 7 0.89 (0.85-0.94) 0 0.50 0.97 6 0.94 (0.80-1.10) 28.6 0.22 0.44 
No  1 0.83 (0.73-0.94)   2 0.90 (0.72-1.13) 0 0.36 1 1.13 (0.80-1.61)   
Physical activity  
 
Yes  7 0.80 (0.76-0.85) 0 0.65 0.09 5 0.89 (0.83-0.96) 23.8 0.26 0.76 3 0.93 (0.79-1.09) 10.9 0.33 0.78 
No  3 0.91 (0.80-1.02) 33.9 0.22 4 0.91 (0.81-1.03) 0 0.84 4 1.04 (0.77-1.40) 49.6 0.11 
Red, processed meat Yes  4 0.84 (0.74-0.94) 69.4 0.02 0.93 2 0.89 (0.71-1.12) 64.4 0.09 0.27 3 0.85 (0.74-0.97) 0 0.51 0.07 
No  6 0.83 (0.76-0.89) 0 0.83 7 0.91 (0.86-0.97) 0 0.92 4 1.12 (0.93-1.36) 0 0.66 
Fruit, vegetables Yes 3 0.81 (0.73-0.89) 50.8 0.13 0.41 2 0.87 (0.76-1.00) 65.5 0.09 0.48 1 0.85 (0.71-1.02)   0.35 
No  7 0.86 (0.80-0.92) 2.9 0.40 7 0.91 (0.85-0.97) 0 0.85 6 1.02 (0.85-1.22) 23.4 0.26 
Folate  Yes  3 0.89 (0.80-0.99) 44.6 0.17 0.10 1 0.94 (0.83-1.05)   0.45 1 0.79 (0.61-1.02)   0.24 
No 7 0.79 (0.74-0.84) 0 0.74 8 0.89 (0.84-0.94) 0 0.60 6 1.01 (0.86-1.18) 19.4 0.29 
Energy intake Yes  9 0.83 (0.78-0.89) 32.9 0.16 0.99 8 0.89 (0.85-0.94) 0 0.57 0.51 6 0.94 (0.80-1.10) 28.6 0.22 0.44 
No  1 0.83 (0.73-0.94   1 1.00 (0.72-1.39)   1 1.13 (0.80-1.61)   
n denotes the number of studies. 
1
 P for heterogeneity within each subgroup, 
2
 P for heterogeneity between subgroups with meta-regression 
analysis, 
3,4
 subgroup analyses restricted to studies that reported results both for men and women, 
5,6
 subgroup analyses restricted to studies that 
reported results both for colon and rectum.  
Table 2. Other dairy products and colorectal cancer 
 
Type of dairy product N RR (95% CI) I
2
 pheterogeneity 
High-fat dairy products 3 0.74 (0.53-1.02) 45 0.16 
Low-fat dairy products 2 0.97 (0.74-1.28) 0 0.78 
Cottage cheese 4 0.82 (0.59-1.14) 43 0.16 
Fermented dairy products 5 0.97 (0.83-1.13) 0 0.83 
Fermented milk 4 0.93 (0.78-1.11) 33 0.22 
Yogurt  2 1.00 (0.67-1.48) 41 0.19 
Butter 2 0.91 (0.58-1.43) 39 0.20 
 
 
 
 
